Overview

Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia

Status:
Completed

Trial end date:
2019-11-13

Target enrollment:

Participant gender:

Summary

Previous studies have shown that increase level of BAFF could promote the settlement of long-lived plasma cells in the spleen of ITP patients treated with anti-CD20. This single-center prospective pilot study, currently in phase IIa, will evaluate the efficacy of a rituximab and belimumab sequential combination treatment. Investigators plan to include 15 patients with persistent ITP over a 24-month inclusion period. Each patient will be followed for 1 year

Phase:

N/A

Details

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Treatments:

Belimumab
Rituximab